Results from a clinical trial of CRISPR gene editing in 14 individuals with a form of inherited blindness show that the treatment is safe and led to measurable improvements in 11 of the participants treated. The Phase I/II trial called BRILLIANCE, was led by principal investigator Eric Pierce, MD, Ph.D., of Mass Eye and Ear, a member of the Mass General Brigham health care system. Findings are reported May 6 in The New England Journal of Medicine.
Medical Xpress – latest medical and health news stories
